JPH0597672A - アミド誘導体含有固形製剤およびその製造方法 - Google Patents

アミド誘導体含有固形製剤およびその製造方法

Info

Publication number
JPH0597672A
JPH0597672A JP3287220A JP28722091A JPH0597672A JP H0597672 A JPH0597672 A JP H0597672A JP 3287220 A JP3287220 A JP 3287220A JP 28722091 A JP28722091 A JP 28722091A JP H0597672 A JPH0597672 A JP H0597672A
Authority
JP
Japan
Prior art keywords
amide derivative
weight
group
polyvinylpyrrolidone
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3287220A
Other languages
English (en)
Japanese (ja)
Inventor
Eiji Watanabe
英二 渡邊
Sawako Koyama
佐和子 小山
Tetsuo Tanaka
哲夫 田中
Masahiro Suzuki
雅博 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Priority to JP3287220A priority Critical patent/JPH0597672A/ja
Priority to TW081107944A priority patent/TW228470B/zh
Priority to CA002079938A priority patent/CA2079938A1/en
Priority to AU26225/92A priority patent/AU637549B1/en
Priority to CN92111372A priority patent/CN1071334A/zh
Priority to EP92402740A priority patent/EP0537070A1/en
Publication of JPH0597672A publication Critical patent/JPH0597672A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP3287220A 1991-10-08 1991-10-08 アミド誘導体含有固形製剤およびその製造方法 Pending JPH0597672A (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP3287220A JPH0597672A (ja) 1991-10-08 1991-10-08 アミド誘導体含有固形製剤およびその製造方法
TW081107944A TW228470B (https=) 1991-10-08 1992-10-06
CA002079938A CA2079938A1 (en) 1991-10-08 1992-10-06 Solid formulation containing amide derivative and method of manufacturing the formulation
AU26225/92A AU637549B1 (en) 1991-10-08 1992-10-07 Solid formulation containing amide derivative and method of manufacturing the formulation
CN92111372A CN1071334A (zh) 1991-10-08 1992-10-08 含酰胺衍生物的固体配方及其制造方法
EP92402740A EP0537070A1 (en) 1991-10-08 1992-10-08 Compositions containing compound TMK688 and its analogs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3287220A JPH0597672A (ja) 1991-10-08 1991-10-08 アミド誘導体含有固形製剤およびその製造方法

Publications (1)

Publication Number Publication Date
JPH0597672A true JPH0597672A (ja) 1993-04-20

Family

ID=17714602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3287220A Pending JPH0597672A (ja) 1991-10-08 1991-10-08 アミド誘導体含有固形製剤およびその製造方法

Country Status (6)

Country Link
EP (1) EP0537070A1 (https=)
JP (1) JPH0597672A (https=)
CN (1) CN1071334A (https=)
AU (1) AU637549B1 (https=)
CA (1) CA2079938A1 (https=)
TW (1) TW228470B (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517470A (ja) * 1999-11-23 2003-05-27 リポシン インコーポレイテッド 薬学的組成物における活性成分の改善された送達のための固体キャリア
JPWO2006046623A1 (ja) * 2004-10-25 2008-05-22 日本たばこ産業株式会社 溶解性及び安定性の改善された固形製剤及びその製造方法
US7432392B2 (en) 2003-08-29 2008-10-07 Japan Tobacco Inc. Ester derivatives and medical use thereof
WO2009001786A1 (ja) * 2007-06-22 2008-12-31 Kaneka Corporation 生理活性物質含有組成物
US7625948B2 (en) 2002-02-28 2009-12-01 Japan Tobacco Inc. Ester compound and medicinal use thereof
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
EP0639376A1 (en) * 1993-08-18 1995-02-22 Terumo Kabushiki Kaisha Liquid composition containing amide derivative
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
ES2278101T3 (es) * 2003-09-17 2007-08-01 Alpharma Aps Composicion de teicoplanina con actividad antibiotica mejorada.
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673684A (en) * 1984-04-04 1987-06-16 Terumo Corporation Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
JPH0660160B2 (ja) * 1985-12-13 1994-08-10 テルモ株式会社 アミド誘導体およびこれを含有する抗アレルギ−剤
JPS63139124A (ja) * 1986-12-01 1988-06-10 Terumo Corp 腎炎治療剤

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517470A (ja) * 1999-11-23 2003-05-27 リポシン インコーポレイテッド 薬学的組成物における活性成分の改善された送達のための固体キャリア
US7625948B2 (en) 2002-02-28 2009-12-01 Japan Tobacco Inc. Ester compound and medicinal use thereof
US7432392B2 (en) 2003-08-29 2008-10-07 Japan Tobacco Inc. Ester derivatives and medical use thereof
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
JPWO2006046623A1 (ja) * 2004-10-25 2008-05-22 日本たばこ産業株式会社 溶解性及び安定性の改善された固形製剤及びその製造方法
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
JP4782695B2 (ja) * 2004-10-25 2011-09-28 日本たばこ産業株式会社 溶解性及び安定性の改善された固形製剤及びその製造方法
WO2009001786A1 (ja) * 2007-06-22 2008-12-31 Kaneka Corporation 生理活性物質含有組成物

Also Published As

Publication number Publication date
AU637549B1 (en) 1993-05-27
TW228470B (https=) 1994-08-21
CA2079938A1 (en) 1993-04-09
EP0537070A1 (en) 1993-04-14
CN1071334A (zh) 1993-04-28

Similar Documents

Publication Publication Date Title
JPH0597672A (ja) アミド誘導体含有固形製剤およびその製造方法
KR100534504B1 (ko) 속붕괴성 의약 조성물
EP1275391B1 (en) Pharmaceutical compositions containing irbesartan and a diuretic
JP2916152B2 (ja) 薬物放出速度調節型製剤
US6511681B2 (en) Aqueous solubility pharmaceutical formulations
KR101151117B1 (ko) 경구 투여가능한 고체 제약 조성물의 제조 방법
TWI389691B (zh) 可口服且具有活性成分快速釋出之固態醫藥劑型
TWI228414B (en) Pharmaceutical composition comprising carvedilol and hydrochlorothiazide, solid dosage form comprising it, and process for the production of the same
JPWO1996025158A1 (ja) アズレン誘導体含有医薬組成物及びその製造方法
JPWO1998029137A1 (ja) 速崩壊性医薬組成物
PL226401B1 (pl) Doustna postać dawkowania zawierająca inhibitor PDE 4 jako składnik aktywny i poliwinylopirolidon jako substancję pomocniczą
HUE028204T2 (en) Pharmaceutical compositions containing the active ingredient nilotinib or a salt thereof
CN100560067C (zh) 盐酸决奈达隆口服药物组合物及其制备方法
HU207948B (en) Process for producing oral pimobendane compositions
KR100908418B1 (ko) 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법
JP5288791B2 (ja) 難水溶性物質含有微細化組成物
JP2705787B2 (ja) 苦味改善易服用性ｈ▲２▼ブロッカー固形製剤
US20120010216A1 (en) Pharmaceutical compositions containing vanoxerine
JP5103173B2 (ja) ジヒドロピリジン系化合物の分解を防止する方法
KR101233235B1 (ko) 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
JP2814513B2 (ja) 溶出性の改良された製剤組成物
JPS61227524A (ja) プラゾシン製剤及びその製法
JPWO2002069932A1 (ja) 発泡性組成物
JP2022072050A (ja) エドキサバンを含有する口腔内崩壊錠
JPH02206A (ja) エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤